SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.4489

Change

+0.04 (+9.54)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-03 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.54 (+0.70%)

USD 238.12B
AMGN Amgen Inc

+1.50 (+0.48%)

USD 165.96B
SNY Sanofi ADR

+0.80 (+1.64%)

USD 122.04B
GILD Gilead Sciences Inc

+0.10 (+0.15%)

USD 85.48B
BIIB Biogen Inc

+1.04 (+0.46%)

USD 33.75B
GRFS Grifols SA ADR

+0.40 (+6.02%)

USD 5.12B
AMRN Amarin Corporation PLC

+0.05 (+7.30%)

USD 0.28B
SCLX Scilex Holding Company

+0.08 (+4.44%)

USD 0.18B
MIRA MIRA Pharmaceuticals Inc. Comm..

+0.01 (+1.69%)

USD 0.01B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.69% 100% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.69% 100% F 85% B
Trailing 12 Months  
Capital Gain -65.20% 22% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.20% 22% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.65% 44% F 22% F
Dividend Return -15.65% 44% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.46% 11% F 36% F
Risk Adjusted Return -32.97% 44% F 25% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector